AU2007220263A1 - Cancer treatments - Google Patents

Cancer treatments Download PDF

Info

Publication number
AU2007220263A1
AU2007220263A1 AU2007220263A AU2007220263A AU2007220263A1 AU 2007220263 A1 AU2007220263 A1 AU 2007220263A1 AU 2007220263 A AU2007220263 A AU 2007220263A AU 2007220263 A AU2007220263 A AU 2007220263A AU 2007220263 A1 AU2007220263 A1 AU 2007220263A1
Authority
AU
Australia
Prior art keywords
oxaliplatin
liposome
cancer
cisplatin
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007220263A
Other languages
English (en)
Inventor
Parthenios Boulikas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2007220263A1 publication Critical patent/AU2007220263A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007220263A 2006-03-03 2007-03-05 Cancer treatments Abandoned AU2007220263A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR20060100144 2006-03-03
GR20060100144A GR20060100144A (el) 2006-03-03 2006-03-03 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
PCT/GR2007/000015 WO2007099377A2 (en) 2006-03-03 2007-03-05 Cancer treatments

Publications (1)

Publication Number Publication Date
AU2007220263A1 true AU2007220263A1 (en) 2007-09-07

Family

ID=38325437

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007220263A Abandoned AU2007220263A1 (en) 2006-03-03 2007-03-05 Cancer treatments

Country Status (17)

Country Link
US (1) US20090053302A1 (OSRAM)
EP (1) EP2001441A2 (OSRAM)
JP (1) JP2009528340A (OSRAM)
KR (1) KR20090023548A (OSRAM)
CN (1) CN101522172A (OSRAM)
AU (1) AU2007220263A1 (OSRAM)
BR (1) BRPI0707059A2 (OSRAM)
CA (1) CA2644566A1 (OSRAM)
EA (1) EA200801912A1 (OSRAM)
GR (1) GR20060100144A (OSRAM)
MA (1) MA30314B1 (OSRAM)
MX (1) MX2008011263A (OSRAM)
NO (1) NO20083927L (OSRAM)
RS (1) RS20080388A (OSRAM)
TN (1) TNSN08345A1 (OSRAM)
WO (1) WO2007099377A2 (OSRAM)
ZA (1) ZA200807934B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
KR20080094473A (ko) * 2007-04-20 2008-10-23 한국화학연구원 음이온성 지질나노입자 및 이의 제조방법
EP2236145B1 (en) * 2008-01-28 2014-05-14 NanoCarrier Co., Ltd. Pharmaceutical composition and combined agent
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
EP2259844A4 (en) * 2008-03-05 2012-02-01 Vicus Therapeutics Llc COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGICAL THERAPIES
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
US20120135064A1 (en) * 2009-05-27 2012-05-31 Northeastern University Conjugated nanodelivery vehicles
EP2481396A4 (en) * 2009-09-21 2014-03-05 Jw Pharmaceutical Corp OXALIPLATIN NANOPARTICLES AND MANUFACTURING METHOD THEREFOR
JP5817053B2 (ja) * 2010-04-02 2015-11-18 国立大学法人 千葉大学 腫瘍特異性を有するリポソーム
CN102133176B (zh) * 2011-03-22 2012-09-05 济南宏瑞创博医药科技开发有限公司 一种奥沙利铂胶束制剂及其制备方法及应用
JP5378469B2 (ja) * 2011-08-11 2013-12-25 学校法人 日本歯科大学 医療用薬剤
EP2883542B1 (en) 2012-08-10 2019-05-01 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
MA37931A1 (fr) * 2012-08-13 2016-07-29 Teni Boulikas Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite
US20150258139A1 (en) * 2012-08-13 2015-09-17 Regulon, Inc. Methods for treatment of cancer using lipoplatin
PL2892524T3 (pl) 2012-09-04 2021-10-25 Eleison Pharmaceuticals, Llc Zapobieganie nawrotom płucnym przy użyciu cisplatyny w kompleksie z lipidami
EA023757B1 (ru) * 2012-12-24 2016-07-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы оксалиплатина
CN105451720A (zh) * 2013-03-13 2016-03-30 马林克罗特有限公司 用于癌症疗法的脂质体奥沙利铂组合物
AU2014245147B2 (en) 2013-03-27 2017-08-31 Les Laboratoires Servier Antitumor agent including low-dose irinotecan hydrochloride hydrate
CN103622912B (zh) * 2013-12-05 2016-02-24 常州金远药业制造有限公司 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法
KR20170132152A (ko) * 2015-02-13 2017-12-01 오피 나노 컴퍼니, 리미티드 나노입자를 이용한 종양 치료 조성물 및 방법
JP2018507227A (ja) 2015-03-03 2018-03-15 キュアポート インコーポレイテッド 二薬搭載リポソーム医薬製剤
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
KR101687735B1 (ko) * 2015-09-18 2016-12-19 서울대학교 산학협력단 신규의 동결건조보조제 및 새로운 인지질 용해용 혼합용매를 이용한 리포좀 동결분체의 제조방법
US20190307690A1 (en) * 2016-05-03 2019-10-10 The American University In Cairo Liposomal Delivery Systems for Oxaliplatin and in Dual Drug Delivery in Combination with Chemo-sensitizing and Chemo-therapeutic agents
WO2017192863A1 (en) * 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN106074379B (zh) * 2016-07-11 2019-01-25 中国科学院上海药物研究所 聚乙二醇化奥沙利铂前药及其制备方法和用途
CN112656764B (zh) * 2020-12-28 2022-09-02 吉林大学 一种紫杉醇铂类共载靶向长循环脂质体及应用
CN114814023B (zh) * 2022-04-24 2024-07-30 江苏省中医院 脂质分子在作为胃癌化疗药耐药的预测性标志物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2046997C (en) * 1990-07-16 2000-12-12 Hiroshi Kikuchi Liposomal products
US6060080A (en) * 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
CN1254234C (zh) * 2000-06-09 2006-05-03 莱古伦公司 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
JP3415131B1 (ja) * 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
CN1681478A (zh) * 2002-08-02 2005-10-12 川塞夫有限公司 铂聚集体及其制备方法
US20070160656A1 (en) * 2003-05-02 2007-07-12 Dziewiszek Krzysztof J Lipid platinum complexes and methods of use thereof
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents

Also Published As

Publication number Publication date
GR20060100144A (el) 2007-10-17
KR20090023548A (ko) 2009-03-05
WO2007099377A2 (en) 2007-09-07
CA2644566A1 (en) 2007-09-07
NO20083927L (no) 2008-09-15
ZA200807934B (en) 2009-11-25
MX2008011263A (es) 2008-12-12
CN101522172A (zh) 2009-09-02
MA30314B1 (fr) 2009-04-01
RS20080388A (sr) 2009-07-15
EA200801912A1 (ru) 2009-02-27
WO2007099377A3 (en) 2008-04-17
EP2001441A2 (en) 2008-12-17
US20090053302A1 (en) 2009-02-26
JP2009528340A (ja) 2009-08-06
BRPI0707059A2 (pt) 2011-04-19
TNSN08345A1 (en) 2009-12-29

Similar Documents

Publication Publication Date Title
US20090053302A1 (en) Cancer treatments
Pillai Nanotechnology toward treating cancer: A comprehensive review
JP7821227B2 (ja) 安定化カンプトテシン医薬組成物
US7311924B2 (en) Compositions and methods for treating cancer
JP5981214B2 (ja) リンパ腫の治療のための組成物および方法
Lu et al. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer
Liu et al. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent
Marzban et al. Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies
CN116635009A (zh) 用于递送抗癌剂的具有改进的治疗指数的组合物和方法
US20230108934A1 (en) Stabilizing Camptothecin Pharmaceutical Compositions
CN115605196A (zh) 用于治疗癌症和癌症耐药性的脂质体制剂
WO2008038291A1 (en) Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy
Gajera et al. An overview of FDA approved liposome formulations for cancer therapy
Webb et al. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine
WO2021173870A1 (en) Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs
US20220087975A1 (en) Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
US20190060234A1 (en) Liposomal Formulations of Platinum-Acridine Anticancer Agents and Methods Thereof
US20200390702A1 (en) Liposomal taxanes for treatment of sclc
HK40070304A (en) Stabilizing camptothecin pharmaceutical compositions
HK40086650A (zh) 用於治疗癌症和癌症耐药性的脂质体制剂
RU2833053C2 (ru) Стабилизирующие фармацевтические композиции камптотецина
Rathi Development and Characterization of Functionalized Nanoconstructs for Effective Treatment of Lung Cancer
Lewi et al. Liposomal drug carriers

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted